Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Epigenetics: Current and future applications that are driving novel drug discovery
Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available. Stryker Corporation is one of the world's leading medical technology companies with a broad base of products in orthopaedics and a significant presence in other areas of the medical device industry. The company was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr Homer Stryker, a leading orthopaedic surgeon and the inventor of several orthopaedic products. In 2007, Stryker sold its out-patient physical therapy business, Physiotherapy Associates, and now segregates its operations into two business segments: Orthopaedic Implants and MedSurg Equipment.
The Orthopaedic Implants segment produces orthopaedic reconstructive (hip, knee and shoulder), trauma, craniomaxillofacial and spinal implant systems; bone cement; and the bone growth factor, OP-1.
The MedSurg Equipment segment manufactures surgical equipment; surgical navigation systems; endoscopic, communications systems; as well as patient handling and emergency medical equipment.
Recent key acquisitions have added to Stryker's capabilities and opened up new markets. In 2009, Stryker's most prominent acquisition was Ascent Healthcare Solutions, which claims to be the market leader in the reprocessing and remanufacturing of medical devices in the US. The company also acquired OtisMed, a software technology company that will focus on customizable instrumentation. In March 2010, Stryker completed the purchase of assets used to manufacture, market and sell the Sonopet Ultrasonic Aspirator technology, which includes precision microsurgical instruments used in neurological and spine procedures.
Stryker's principal operations are located in the US and it has additional manufacturing facilities in several other countries including Ireland, Germany, France, Switzerland, Puerto Rico, Canada and China. Its products are sold in more than 100 countries through local dealers and direct sales efforts.
In 2009, Stryker generated net earnings of US$1.1 billion on sales of US$6.7 billion. As at 31st December 2009, the company had 18,582 employees worldwide.
This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company's major competitors?
Key recent events in an "at a glance" format
Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Strategic Focus
Investigates the company's aims and its areas of focus
Products
Core product areas, key brands, product approvals and launches
Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
Identifying the company's manufacturing locations
Sales and marketing facilities
Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions and Divestments
Litigation
Key Corporate Events
Contents
The Business Implications............1
Chapter 1 - Epigenetics Defined 3
Executive Summary...4
Epigenetics defined..................4
Epigenetics de fined ..... 5
Epigenetic mechanisms................6
DNA methylation...6
Figure 1: Schematic showing the epigenetic mechanisms of DNA methylation and histone modification .................. 6
Chromatin remodelling and histone modifications .......7
Figure 2: Examples of covalent histone post-translational modifications ....... 7
Non-coding RNA....8
Figure 3: miRNA processing pathway... 8
Unravelling the power of epigenetics............9
EXPERT COMMENTARY: Professor Stephan Beck, University College London Cancer Institute
Consortia for the study of epigenomics.........10
Which epigenomes and what to study? .....10
Applications of epigenomic data..................10
New opportunities for biomarker discovery and drug targeting
Conclusion and report outline...................11
Chapter 2 - Technical Challenges in Epigenetic R&D 13
Executive Summary.14
Technical challenges in epigenetic R&D....14
Technical challenges in epigenetic R&D..... 15
EXPERT COMMENTARY: Dr Chris Adams, Senior R&D Manager/Epigenetics, Life Technologies 15. 15
Next generation sequencing.....16
Table 1: Platforms for next generation sequencing 16
Table 2: Third generation sequencing platforms..... 17
DNA methylation.....17
Table 3: Methods for studying DNA methylation and their limitations ........... 17
Table 4: Suppliers of research tools for the study of DNA methylation............ 18
Chromatin structure and histone modifications............19
Figure 4: Schematic of a chromatin immunoprecipitation experiment ......... 19
Table 5: Suppliers of research tools for the study of histone and chromatin modifications ................... 20
microRNA................. 20
Table 6: Suppliers of research tools for the study of miRNA........ 21
Conclusion.................21
Chapter 3 - Epigenetics in Drug Discovery & Development 23
Executive Summary.24
Epigenetics in drug discovery & development.............24
Epigenetics in drug discover y & development............. 25
Introduction............. 25
Figure 5: Proteins involved in the modification of histones......... 25
Figure 6: Number of drugs targeting epigenetic mechanisms by mechanism and stage of development ................ 26
Epigenetics in cancer...................26
Epigenetic drug targets in cancer: DNA methyltransferases
Table 7: Approved drugs targeting DNMTs.............. 27
Epigenetic drug targets in cancer: HDAC inhibitors.....28
Non-selective HDAC inhibitors...................28
Table of Contents
Espicom Business Intelligence iv August 2010
Table of Contents Epigenetics: Current and Future Applications
Table 8: Pan-HDAC inhibitors in clinical development ............... 28
EXPERT COMMENTARY: Dr Bernd Hentsch, Chief Development Officer, 4SC AG
Selective HDAC inhibitors.......30
Table 9: Selective HDAC inhibitors....... 30
EXPERT COMMENTARY: Dr David Simmons (CSO) & Dr Gitte Neubauer (VP Research Operations), Cellzome 31. 31
Beyond DNMT and HDAC inhibition: New targets .......32
Table 10: Companies developing drugs for novel epigenetic targets.............. 33
EXPERT COMMENTARY: Dr Robert Gould, CEO, Epizyme Inc
EXPERT COMMENTARY: Martin Bonde, CEO, EpiTherapeutics
Cancer the first frontier, where next?...........35
Table 11: Companies developing therapeutics for epigenetic mechanisms in diseases other than cancer ................. 35
Non-coding RNAs....35
Table 12: Companies developing therapeutic strategies related to miRNAs... 35
Table 13: Therapeutic areas for miRNA-based therapeutic discovery............. 36
EXPERT COMMENTARY: Dr. Andreas G. Bader, Associate Director of Research, Mirna Therapeutics, Inc.37. 37
The future................. 38
Chapter 4 - Epigenetics in Clinical Diagnostics 39
Executive Summary 40
Epigenetics in clinical diagnostics.............40
Epigenetics in clinica l diagnostics.............. 41
Introduction..............41
DNA methylation patterns.........41
Table 14: Companies developing diagnostics to detect aberrant DNA methylation patterns ............... 41
Epigenomics AG...42
Figure 7: Epigenomics' development programme.. 42
OncoMethylome Sciences......43
Figure 8: OncoMethylome Sciences' development programme.. 43
Orion Genomics...44
Figure 9: Orion Genomics' product development pipeline.......... 44
Histone modifications................ 45
miRNAs. 45
Rosetta Genomics45
Table 15: Approved and developmental diagnostic products from Rosetta Genomics ..... 45
Asuragen Diagnostics.............46
Exiqon A/S............46
Table 16: Exiqon's miRNA-based diagnostic pipeline.................. 47
Biomarkers and personalised medicine......47
Table 17: Diagnostic/pharma partnerships for epigenetic biomarker discovery................ 47
Outlook. 48
Chapter 5 - Players, Alliances & Acquisitions 49
Executive Summary 50
Players, alliances & acquisitions................50
Player s, alliance s & ac quisitions................. 51
Company activities at a glance – Therapeutics..............51
Table 18: Areas of focus for companies developing drugs for epigenetic targets............... 51
4SC AG, Planegg-Martinsried, Germany...52
Acetylon Pharmaceuticals Inc, Boston, MA..................52
Celgene Corporation, Summit, NJ .............52
Celleron Therapeutics, Oxon, UK...............52
Cellzome, Cambridge, UK, and Heidelberg, Germany.53
Curis Inc, Cambridge MA ........53
Espicom B August 2010 Business Intelligence v
Epigenetics: Current and Future Applications Table of Contents
Chroma Therapeutics Ltd, Oxon, UK .........53
Constellation Pharmaceuticals, Cambridge, MA .........54
EnVivo Pharmaceuticals, Watertown, MA.54
EpiTherapeutics Aps, Copenhagen, Denmark .............54
Epizyme, Cambridge, MA .......54
MethylGene, Inc. Montreal, Québec .........55
Mirna Therapeutics, Austin, TX..................55
miRagen Therapeutics, Boulder, CO..........55
Pharmacyclics, Sunnyvale, CA ...................55
Progen Pharmaceuticals, Brisbane, Australia..............56
Regulus Therapeutics, Torrey Pines, CA....56
Repligen Corporation, Waltham, MA ........56
Santaris Pharma A/S, Denmark..................56
SuperGen, Dublin, CA.............56
Syndax Pharmaceuticals, Waltham, MA ...57
TopoTarget, Copenhagen, Denmark .........57
Alliances with market leaders – Therapeutics............... 58
Table 19: Alliances, acquisitions and mergers in the field of epigenetics since 2007 ......... 59
Table 20: Areas of focus for companies developing diagnostic tests based on epigenetics ...................60
Asuragen Inc, Austin, TX.........60
Epigenomics AG, Berlin, Germany.............60
Exiqon, Copenhagen, Denmark.................60
OncoMethylome Sciences, Durham, NC....61
Orion Genomics, Saint Louis, MO ..............61
Rosetta Genomics, Rehovot, Israel ...........61
Alliances with market leaders – Diagnostics..................61
Conclusion................ 62
Chapter 6 - Outlook & Future of Epigenetic Research 63
Executive Summary 64
Outlook & future of epigenetic research. 65
Epigenetics research now ......... 65
Figure 10: Progress in epigenetics related therapeutics and diagnostics over the next 5 years ............ 65
Therapeutic launches and new indications over the next 5 years 66
Table 21: Revenues generated by Vidaza, Dacogen and Zolinza in 2009........ 66
New combinations and a changing therapeutic paradigm in cancer 67
Table 22: Examples of clinical trials of combinations of DNMTi, HDACi and chemotherapy .................. 67
Table 23: Examples of clinical trials of drug combinations including panobinostat .........68
New diagnostic products........69
Table 24: New diagnostic products identifying epigenetic biomarkers that will be launched to the market over the next few years 69. 69
Next generation sequencing..69
Epigenetics research in 5 to 10 years time..70
Figure 11: Progress in epigenetics related therapeutics and diagnostics over the next 5 to 10 years ..... 70
Therapeutic launches..............70
Therapeutics and companion diagnostics for novel epigenetic targets 71
Epigenetics research more than 10 years from now.... 72
Figure 12: Progress in epigenetics-related therapeutics and diagnostics 10 years + ....... 72
Conclusions.............. 73
Glossary.... 74
Biography of the author............ 75
References 76
Endnotes... 79__
To order this report:
Genomics Industry: Epigenetics: Current and future applications that are driving novel drug discovery
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article